Precigen Partners with RRPF to Raise Awareness for Recurrent Respiratory Papillomatosis (RRP)

On June 11, 2026, Precigen, Inc. (PGEN) joins forces with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to acknowledge the third annual International RRP Awareness Day. This observance is essential not just for highlighting the rare disease recurrent respiratory papillomatosis (RRP), which affects about 27,000 adults in the United States and over 170,000 globally, but also for promoting understanding among affected communities. RRP, a condition resulting from HPV infections, presents significant challenges to those impacted, particularly concerning their voice, breathing, and overall daily life. Kim McClellan, President of the RRPF, underlines the importance of sharing stories from patients to increase support and awareness about this under-acknowledged disease.

Precigen's Groundbreaking Treatment Takes Center Stage

In a remarkable stride for patient care, Precigen’s HPV-specific immunotherapy received FDA approval in August 2025, making it the only approved treatment option for adults suffering from RRP. Helen Sabzevari, President and CEO of Precigen, emphasizes that this achievement not only marks a significant regulatory milestone but also highlights how crucial patient narratives are in guiding scientific advancements. The collaboration between Precigen and RRPF aims to accentuate patient voices and cultivate ongoing progress in both RRP treatment and support frameworks.

Awareness and Community Engagement Efforts

As Precigen spearheads initiatives related to RRP, it utilizes patient stories to further enhance its messaging and outreach. The current campaign showcases testimonials and experiences from the RRP community via community quotes and videos featured on rrpawareness.org. This multifaceted approach not only bolsters awareness but also builds a supportive network for individuals coping with RRP, demonstrating how together, advocacy and innovative therapies can forge new pathways for those challenged by this condition.

Commitment to Patients and Future Innovations

With focused efforts and strategic partnerships, Precigen continues to solidify its position in the biopharmaceutical landscape, aiming to improve the quality of life for patients affected by RRP and similar conditions. The company reinforces its dedication to amplifying patient voices, crafting solutions that are informed by those living with the disease, thereby instilling hope for the future of treatment in this niche yet impactful field.